Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection

Pediatric Infectious Disease Journal

Volumn 21, Issue 4, 2002, Pages 315-321

  Madhi, Shabir A ^a   Petersen, Karen ^a   Khoosal, Manikant ^a   Huebner, Robin E ^a   Mbelle, Nontombi ^a   Mothupi, Rosalia ^a   Saloojee, Haroon ^a   Crewe Brown, Heather ^a   Klugman, Keith P ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Conjugate vaccines; Haemophilus influenzae type b; Human immunodeficiency virus; Pneumonia

Indexed keywords

ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; ORAL POLIOMYELITIS VACCINE; VIRUS DNA;

ARTICLE; BACTERIAL INFECTION; BLOOD CULTURE; CEREBROSPINAL FLUID CULTURE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SOUTH AFRICA;

ANTIBODY FORMATION; COHORT STUDIES; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MALE; PREVALENCE; PROSPECTIVE STUDIES; SOUTH AFRICA;

EID: 0036223722     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200204000-00011     Document Type: Article

References (31)

1. Large scale, post licensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: Practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections
2. A randomised trial of Haemophilus influenzae type b tetanus protein conjugate for the prevention of pneumonia and meningitis in Gambian infants
3. Progress toward eliminating Haemophilus influenzae type b disease among infants and children: United States, 1987-1997
4. Postlicensure surveillance for Haemophilus influenzae type b invasive disease after use of Haemophilus influenzae type b oligosaccharide CRM197 conjugate vaccine in a large defined United States population: A four-year eight-month follow-up
5. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: Global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates
6. Persistence of antibody responses to Haemophilus influenzae type b polysaccharide conjugate vaccine in children with vertically acquired human immunodeficiency virus infection
7. The immunogenicity of Haemophilus influenzae type b conjugate vaccines in children born to human immunodeficiency virus-infected women: Women and Infants Transmission Study Group
8. Response of human immunodeficiency virus-exposed and -infected infants to Haemophilus influenzae type b conjugate vaccine
9. The immunogenicity of Haemophilus influenzae type b conjugate (HbOC) vaccine in human immunodeficiency virus-infected and uninfected infants
10. Invasive bacterial infections in children with HIV infection
11. Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency virus type 1-infected children
12. The impact of human immunodeficiency virus type-1 infection on the epidemiology and outcome of bacterial meningitis in South African children
13. Impact of human immunodeficiency virus type-1 on the disease spectrum of Streptococcus pneumoniae in South African children
14. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine
15. Effect of breastfeeding on the vertical transmission of HIV-1 in Soweto, South Africa
16. AIDS- the Baragwanath experience, Part 1: Epidemiology of HIV infection at Baragwanath Hospital; 1988-1990
17. 1994 Revised classification system for human immunodeficiency virus infection in children <13 years of age
18. Immunoglobulin deficiency and idiotype expression in children developing Haemophilus influenzae type b disease after vaccination with conjugate vaccine: The Collaborative Study Group
19. Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure in childhood
20. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome
21. Pediatric acquired immunodeficiency syndrome: Demonstration of B lymphocyte defects in vitro
22. Invasive pneumococcal disease in the immunocompromised host
23. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b
24. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines
25. Prevention of Haemophilus influenzae type b colonization by vaccination: Correlation with serum anti-capsular IgG concentration